Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia

Akira Ito, Yuko Kuga, Hiroyuki Honda, Hiroyuki Kikkawa, Atsushi Horiuchi, Yuji Watanabe, Takeshi Kobayashi

Research output: Contribution to journalArticle

242 Citations (Scopus)

Abstract

Anti-HER2 antibody can induce antitumor responses, and can be used in delivering drugs to HER2-overexressing cancer. Previously, we produced hyperthermia using magnetite nanoparticles that generate heat in an alternating magnetic field. In the present study, we constructed anti-HER2 immunoliposomes containing magnetite nanoparticles, which act as tumor-targeting vehicles, combining anti-HER2 antibody therapy with hyperthermia. The magnetite nanoparticle-loaded anti-HER2 immunoliposomes exerted HER2-mediated antiproliferative effects on SKBr3 breast cancer cells in vitro. Moreover, 60% of magnetite nanoparticles were incorporated into SKBr3, and the cells were then heated at 42.5°C under an alternating magnetic field, resulting in strong cytotoxic effects. These results suggest that this novel therapeutic tool is applicable to treatment of HER2-overexpressing cancer.

Original languageEnglish
Pages (from-to)167-175
Number of pages9
JournalCancer Letters
Volume212
Issue number2
DOIs
Publication statusPublished - Aug 30 2004

Fingerprint

Magnetite Nanoparticles
Fever
Antibodies
Magnetic Fields
Anti-Idiotypic Antibodies
Neoplasms
Therapeutics
Hot Temperature
Breast Neoplasms
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ito, A., Kuga, Y., Honda, H., Kikkawa, H., Horiuchi, A., Watanabe, Y., & Kobayashi, T. (2004). Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Letters, 212(2), 167-175. https://doi.org/10.1016/j.canlet.2004.03.038

Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. / Ito, Akira; Kuga, Yuko; Honda, Hiroyuki; Kikkawa, Hiroyuki; Horiuchi, Atsushi; Watanabe, Yuji; Kobayashi, Takeshi.

In: Cancer Letters, Vol. 212, No. 2, 30.08.2004, p. 167-175.

Research output: Contribution to journalArticle

Ito, A, Kuga, Y, Honda, H, Kikkawa, H, Horiuchi, A, Watanabe, Y & Kobayashi, T 2004, 'Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia', Cancer Letters, vol. 212, no. 2, pp. 167-175. https://doi.org/10.1016/j.canlet.2004.03.038
Ito, Akira ; Kuga, Yuko ; Honda, Hiroyuki ; Kikkawa, Hiroyuki ; Horiuchi, Atsushi ; Watanabe, Yuji ; Kobayashi, Takeshi. / Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. In: Cancer Letters. 2004 ; Vol. 212, No. 2. pp. 167-175.
@article{780f9909764340d3bc146d468bbddb64,
title = "Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia",
abstract = "Anti-HER2 antibody can induce antitumor responses, and can be used in delivering drugs to HER2-overexressing cancer. Previously, we produced hyperthermia using magnetite nanoparticles that generate heat in an alternating magnetic field. In the present study, we constructed anti-HER2 immunoliposomes containing magnetite nanoparticles, which act as tumor-targeting vehicles, combining anti-HER2 antibody therapy with hyperthermia. The magnetite nanoparticle-loaded anti-HER2 immunoliposomes exerted HER2-mediated antiproliferative effects on SKBr3 breast cancer cells in vitro. Moreover, 60{\%} of magnetite nanoparticles were incorporated into SKBr3, and the cells were then heated at 42.5°C under an alternating magnetic field, resulting in strong cytotoxic effects. These results suggest that this novel therapeutic tool is applicable to treatment of HER2-overexpressing cancer.",
author = "Akira Ito and Yuko Kuga and Hiroyuki Honda and Hiroyuki Kikkawa and Atsushi Horiuchi and Yuji Watanabe and Takeshi Kobayashi",
year = "2004",
month = "8",
day = "30",
doi = "10.1016/j.canlet.2004.03.038",
language = "English",
volume = "212",
pages = "167--175",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia

AU - Ito, Akira

AU - Kuga, Yuko

AU - Honda, Hiroyuki

AU - Kikkawa, Hiroyuki

AU - Horiuchi, Atsushi

AU - Watanabe, Yuji

AU - Kobayashi, Takeshi

PY - 2004/8/30

Y1 - 2004/8/30

N2 - Anti-HER2 antibody can induce antitumor responses, and can be used in delivering drugs to HER2-overexressing cancer. Previously, we produced hyperthermia using magnetite nanoparticles that generate heat in an alternating magnetic field. In the present study, we constructed anti-HER2 immunoliposomes containing magnetite nanoparticles, which act as tumor-targeting vehicles, combining anti-HER2 antibody therapy with hyperthermia. The magnetite nanoparticle-loaded anti-HER2 immunoliposomes exerted HER2-mediated antiproliferative effects on SKBr3 breast cancer cells in vitro. Moreover, 60% of magnetite nanoparticles were incorporated into SKBr3, and the cells were then heated at 42.5°C under an alternating magnetic field, resulting in strong cytotoxic effects. These results suggest that this novel therapeutic tool is applicable to treatment of HER2-overexpressing cancer.

AB - Anti-HER2 antibody can induce antitumor responses, and can be used in delivering drugs to HER2-overexressing cancer. Previously, we produced hyperthermia using magnetite nanoparticles that generate heat in an alternating magnetic field. In the present study, we constructed anti-HER2 immunoliposomes containing magnetite nanoparticles, which act as tumor-targeting vehicles, combining anti-HER2 antibody therapy with hyperthermia. The magnetite nanoparticle-loaded anti-HER2 immunoliposomes exerted HER2-mediated antiproliferative effects on SKBr3 breast cancer cells in vitro. Moreover, 60% of magnetite nanoparticles were incorporated into SKBr3, and the cells were then heated at 42.5°C under an alternating magnetic field, resulting in strong cytotoxic effects. These results suggest that this novel therapeutic tool is applicable to treatment of HER2-overexpressing cancer.

UR - http://www.scopus.com/inward/record.url?scp=3442878768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3442878768&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2004.03.038

DO - 10.1016/j.canlet.2004.03.038

M3 - Article

C2 - 15279897

AN - SCOPUS:3442878768

VL - 212

SP - 167

EP - 175

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -